Elevation of CA 125 and CA 19-9 in patients with end-stage liver disease

International Journal of Biological Markers

Volumn 27, Issue 2, 2012, Pages 147-151

  Singhal, Ashish ^a   Lander, Elaine ^a   Karachristos, Andreas ^a   Daly, Ellen ^a   Dowling, Phyllis ^a   Patel, Vishal ^a   Maloo, Manoj ^a   Jain, Ashokkumar ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

CA 125; CA 19 9; Liver; Markers; MELD; Tumor

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; ASCITES; DISEASE SEVERITY; END STAGE LIVER DISEASE; FEMALE; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; BIOLOGICAL MARKERS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; END STAGE LIVER DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84871066482     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9139     Document Type: Article

References (24)

1. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002; 48: 1151-1159.
2. Locker G Y, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
3. Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA125 levels in patients with serosal involvement? A clinical dilemma. Oncology 2003; 65: 1-6.
4. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumor marker. Br J Cancer 1984; 50: 765-769.
5. NIH Consensus Development Panel on Ovarian Cancer.Ovarian cancer: screening, treatment, and follow-up. JAMA 1995; 273: 491-497.
6. Molina R, Filella X, Bruix J, et al. Cancer antigen CA 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991; 37: 1379-1383.
7. Collazos J, Genolla J, Ruibal A. CA 125 serum levels in patients with non-neoplastic liver disease. A clinical and laboratory study. Scand J Clin Lab Invest 1992; 52: 201-206.
8. Kadayifci A, Simsek H, Savas MC, Toppare M. Serum tumor markers in chronic liver disease. Neoplasma 1996; 43: 17-21.
9. Dibaise JK, Donovan JP. Markedly elevated CA125 in hepatic cirrhosis: two case illustrations and review of the literature. J Clin Gastroenterol 1999; 28:159-161.
10. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10 (Suppl 4): 145-149.
11. Okusaka T, Yamada T, Maekawa M. Serum tumor markers for pancreatic cancer: the dawn of new era? J Pancreas 2006; 7: 332-336.
12. Kodama T, Satoh H, Ishikawa H, et al. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 2007; 21: 103-106.
13. Mathurin P, Cadranel JF, Bouraya D, et al. Marked increase in serum CA 19-9 level in patients with alcoholic cirrhosis: report of four cases. Eur J Gastroenterol Hepatol 1996; 8: 1129-1131.
14. Ventrucci M, Pozzato P, Cipolla A, et al. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 2009; 41: 357-363.
15. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987; 59: 213-217.
16. Zuckerman E, Lanir A, Sabo E, et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 1613-1618.
17. Deschênes M, Michel RP, Alpert E, Barkun JS, Metrakos P, Tchervenkov J Elevation of CA-125 level is due to abdominal distension in liver transplantation candidates. Transplantation 2001; 72: 1519-1522.
18. Almudevar Bercero E, Garcia-Rostan Perez GM, Garcia Bragado F, Jimenez C. Prognostic value of high serum levels of CA 125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 1997; 31: 267-273.
19. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22: 1203-1214.
20. Sari R, Yildirim B, Sevinc A, Hilmioglu F. Re. Zuckerman et al. Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. Am J Gastroenterol 2001; 96: 253-254.
21. Leggio L, Abenavoli L, D'Angelo C, et al. Marked decrease of serum Ca 125 levels after Denver shunt placement in a patient with cirrhosis and refractory ascites. Dig Dis Sci 2006; 51: 1644-1646.
22. Kitagawa Y, Iwai M, Muramatsu A, et al. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues. Histopathology 2002; 40: 472-479.
23. Schoniger-Ekele M, Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci 2006; 51: 338-345.
24. Bertino G, Ardiri AM, Calvagno GS, Boemi PM. In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology. Dig Liver Dis 2010; 42: 458-459.